Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 311-315

  Zdrenghea, Mihnea T ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TUBULIN; APHIDICOLIN; BELINOSTAT; BETA INTERFERON; BUTYRIC ACID; CD20 ANTIBODY; CISPLATIN; FLUOROURACIL; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90; HISTAMINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 15; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN P53; RETINOID; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CUTANEOUS T CELL LYMPHOMA; CYTOKINE INDUCED KILLER CELL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EXOCYTOSIS; FOOD AND DRUG ADMINISTRATION; GAMMA IRRADIATION; GENE EXPRESSION; HEAT SHOCK; HIGH RISK PATIENT; HISTONE ACETYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; LIFE EXPECTANCY; MAJOR HISTOCOMPATIBILITY COMPLEX; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIGENE FAMILY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; THERAPY EFFECT; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR GROWTH; ULTRAVIOLET RADIATION; UPREGULATION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; INTERLEUKIN-15; MODELS, THEORETICAL;

EID: 84880043898     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.021     Document Type: Article

References (85)

1. Nakagawa M., Oda Y., Eguchi T., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007, 18:769-774.
2. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280:168-176.
3. Pollyea D.A., Kohrt H.E., Medeiros B.C. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 2011, 152:524-542.
4. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 29:487-494.
5. Melnick A.M. Epigenetics in AML. Best Pract Res Clin Haematol 2010, 23:463-468.
6. Bradbury C.A., Khanim F.L., Hayden R., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19:1751-1759.
7. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. J Biomed Biotechnol 2011, 2011:875824.
8. Mund C., Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays 2010, 32:949-957.
9. Atadja P.W. HDAC inhibitors and cancer therapy, Progress in drug research. Fortschritte der Arzneimittelforschung 2011, 67:175-195.
10. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
11. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
12. StatBite: FDA oncology drug product approvals in 2009. J Natl Cancer Inst 2010, 102:219.
13. Butler K.V., Kalin J., Brochier C., Vistoli G., Langley B., Kozikowski A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010, 132:10842-10846.
14. Aldana-Masangkay G.I., Rodriguez-Gonzalez A., Lin T., et al. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells. Leuk Lymphoma 2011, 52:1544-1555.
15. Hackanson B., Rimmele L., Benkisser M., et al. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leuk Res 2012, 36:1055-1062.
16. Insinga A., Monestiroli S., Ronzoni S., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005, 11:71-76.
17. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
18. Zhang B., Strauss A.C., Chu S., et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010, 17:427-442.
19. Togi S., Kamitani S., Kawakami S., et al. HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. Biochem Biophys Res Commun 2009, 379:616-620.
20. Rosato R.R., Kolla S.S., Hock S.K., et al. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 2010, 285:10064-10077.
21. Robert T., Vanoli F., Chiolo I., et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 2011, 471:74-79.
22. Cellai C., Balliu M., Laurenzana A., et al. The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells. J Cell Mol Med 2012, 16:1758-1765.
23. Armeanu S., Bitzer M., Lauer U.M., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65:6321-6329.
24. Kato N., Tanaka J., Sugita J., et al. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells. Leukemia 2007, 21:2103-2108.
25. Zhang C., Wang Y., Zhou Z., Zhang J., Tian Z. Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 2009, 58:1275-1285.
26. Eagle R.A., Jafferji I., Barrow A.D. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev 2009, 5:22-34.
27. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
28. Skov S., Pedersen M.T., Andresen L., Straten P.T., Woetmann A., Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005, 65:11136-11145.
29. Andresen L., Jensen H., Pedersen M.T., Hansen K.A., Skov S. Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells. J Immunol 2007, 179:8235-8242.
30. Diermayr S., Himmelreich H., Durovic B., et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008, 111:1428-1436.
31. Poggi A., Catellani S., Garuti A., Pierri I., Gobbi M., Zocchi M.R. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 2009, 23:641-648.
32. Poggi A., Zancolli M., Boero S., Catellani S., Musso A., Zocchi M.R. Differential survival of gammadeltaT cells, alphabetaT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. Int J Cancer 2011, 129:387-396.
33. Huang B., Sikorski R., Sampath P., Thorne S.H. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011, 34:289-296.
34. Lu X., Ohata K., Kondo Y., Espinoza J.L., Qi Z., Nakao S. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis. Cancer Sci 2010, 101:609-615.
35. Yamanegi K., Yamane J., Kobayashi K., et al. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 2010, 24:1621-1627.
36. Grabiec A.M., Korchynskyi O., Tak P.P., Reedquist K.A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012, 71:424-431.
37. Hauschild A., Trefzer U., Garbe C., et al. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Res 2008, 18:274-278.
38. Gurvich N., Tsygankova O.M., Meinkoth J.L., Klein P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004, 64:1079-1086.
39. Schaefer E.W., Loaiza-Bonilla A., Juckett M., et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009, 94:1375-1382.
40. Kennedy M.K., Glaccum M., Brown S.N., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780.
41. Agostini C., Siviero M., Facco M., et al. Antiapoptotic effects of IL-15 on pulmonary Tc1 cells of patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 2001, 163:484-489.
42. + memory T cells. Proc Natl Acad Sci USA 2002, 99:6192-6197.
43. + T cells following a microbe exposure. J Immunol 2002, 168:1198-1203.
44. + T cells. J Immunol 2008, 180:4391-4401.
45. Fehniger T.A., Caligiuri M.A. Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol 2001, 20:503-534.
46. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
47. + T cell homeostasis. J Exp Med 2004, 200:825-834.
48. Lodolce J.P., Boone D.L., Chai S., et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 1998, 9:669-676.
49. Schluns K.S., Stoklasek T., Lefrancois L. The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both?. Int J Biochem Cell Biol 2005, 37:1567-1571.
50. Giron-Michel J., Giuliani M., Fogli M., et al. Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood 2005, 106:2302-2310.
51. Mortier E., Quemener A., Vusio P., et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006, 281:1612-1619.
52. Rubinstein M.P., Kovar M., Purton J.F., et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 2006, 103:9166-9171.
53. Bergamaschi C., Rosati M., Jalah R., et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 2008, 283:4189-4199.
54. Onu A., Pohl T., Krause H., Bulfone-Paus S. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J Immunol 1997, 158:255-262.
55. Bamford R.N., DeFilippis A.P., Azimi N., Kurys G., Waldmann T.A. The 5' untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol 1998, 160:4418-4426.
56. Budagian V., Bulanova E., Orinska Z., et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem 2004, 279:42192-42201.
57. Mortier E., Bernard J., Plet A., Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004, 173:1681-1688.
58. + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
59. Rettinger E., Kuci S., Naumann I., et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012, 14:91-103.
60. Waldmann T.A., Lugli E., Roederer M., et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 2011, 117:4787-4795.
61. Roberts A.I., Lee L., Schwarz E., et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001, 167:5527-5530.
62. Sutherland C.L., Chalupny N.J., Schooley K., VandenBos T., Kubin M., Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002, 168:671-679.
63. Meresse B., Chen Z., Ciszewski C., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004, 21:357-366.
64. Zhang C., Zhang J., Sun R., Feng J., Wei H., Tian Z. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. Int Immunopharmacol 2005, 5:1057-1067.
65. Zwirner N.W., Fuertes M.B., Girart M.V., Domaica C.I., Rossi L.E. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 2007, 18:159-170.
66. Zhang C., Niu J., Zhang J., Wang Y., Zhou Z., Tian Z. Opposing effects of interferon-alpha and interferon-gamma on the expression of major histocompatibility complex class I chain-related A in tumors. Cancer Sci 2008, 99:1279-1286.
67. Boyiadzis M., Memon S., Carson J., et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant 2008, 14:290-300.
68. Oppenheim D.E., Roberts S.J., Clarke S.L., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005, 6:928-937.
69. Ebihara T., Masuda H., Akazawa T., et al. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Int Immunol 2007, 19:1145-1155.
70. Zhou Z., Zhang C., Zhang J., Tian Z. Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoS One 2012, 7:e36928.
71. Cerwenka A., Lanier L.L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 2003, 61:335-343.
72. Salih H.R., Antropius H., Gieseke F., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
73. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
74. Dunn C., Chalupny N.J., Sutherland C.L., et al. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 2003, 197:1427-1439.
75. Groh V., Wu J., Yee C., Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
76. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004, 114:560-568.
77. Jinushi M., Takehara T., Tatsumi T., et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol 2005, 43:1013-1020.
78. Duan X., Deng L., Chen X., et al. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer. Med Oncol 2011, 28:466-474.
79. Coudert J.D., Zimmer J., Tomasello E., et al. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood 2005, 106:1711-1717.
80. Wiemann K., Mittrucker H.W., Feger U., et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005, 175:720-729.
81. Wang H., Ruan Z., Wang Y., et al. MHC class I chain-related molecules induced on monocytes by IFN-gamma promote NK cell activation. Mol Immunol 2008, 45:1548-1556.
82. Szczepanski M.J., Szajnik M., Welsh A., Foon K.A., Whiteside T.L., Boyiadzis M. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 2010, 59:73-79.
83. Aurelius J., Martner A., Brune M., et al. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells. Haematologica 2012, 97:1904-1908.
84. Brune M., Castaigne S., Catalano J., et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006, 108:88-96.
85. Cheever M.A. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008, 222:357-368.